I Holland offers free trial of its innovative tool management system
System allows tablet manufacturers to keep a record of tablet quantities by number of tablets, work order or batch information to ensure production is run efficiently.
I Holland is giving its customers the opportunity to sample its innovative IH-TMS, which allows proactive monitoring of tool rotations and tooling inventory and maintenance.
IH-TMS software has been specifically developed to maintain efficient, well-organised and in-depth monitoring of tablet production, an extremely important procedure in pharmaceutical tablet manufacture. Without a system that controls the process effectively, there can be adverse effects to the bottom line.
To demonstrate just how well the system works, I Holland is giving its customer’s a trial copy. Andy Dumelow, I Holland’s PharmaCare® Product Manager explains: “We wanted to show just how easy IH-TMS is to incorporate into a company’s manufacturing process, and how well it performs on monitoring and managing tooling. For a limited time, we are giving customers the opportunity to try the software for free so they can see first-hand how much of a difference it makes in improving their current system.
“The stand-alone system allows tablet manufacturers to keep a record of tablet quantities by number of tablets, work order or batch information to ensure production is run efficiently. It also incorporates an in-depth guide to tooling specification and troubleshooting so any problems flagged up by IH-TMS can be rectified. In addition, it has the capability to archive tablet and tool images and drawings and incorporates an alarm to alert users of any problems including over compression, tooling replacements or when maintenance is required.
“The free demonstration is open to companies from around the world and incorporates the flexibility of using any language, including characters used in, for example, Japanese, Chinese, Arabic and Russian making it a globally diverse management system.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.